More recently, osimertinib has been shown to be associated with disease-free survival (median was not reached in patients on the osimertinib arm compared with 27.5 months on the placebo arm (hazard ratio, 0.20; 95% confidence interval, 0.15 to 0.27; p < 0.0001)) in patients with stage IB to IIIA NSCLCs with completely resected tumors following standard platinum-based adjuvant chemotherapy, setting the scene for further changes in the treatment landscape of EGFR-mutant lung adenocarcinomas [5]. Here, EGFR is linked to lung adenocarcinoma.